Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

ABSTRACT:

Introduction

Activating mutations in the epidermal growth factor receptor gene (EGFR) predict for prolonged progression-free survival in patients with advanced non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (EGFR-TKIs) versus chemotherapy. Long-term survival outcomes, however, remain undefined. The objective of this study was to determine the 5-year survival in these patients and identify clinical factors associated with overall survival (OS).

Methods

Patients with EGFR-mutant metastatic lung adenocarcinoma who had been treated with erlotinib or gefitinib at Dana-Farber Cancer Institute between 2002 and 2009 were included. OS was analyzed.

Results

Among 137 patients, median progression-free survival and OS were 12.1 months (95% CI: 10.

SUBMITTER: Lin JJ 

PROVIDER: S-EPMC4979601 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature